Picture of Abingdon Health logo

ABDX Abingdon Health News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

REG - Abingdon Health PLC - Exercise of Options and TVR

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220520:nRST3037Ma&default-theme=true

RNS Number : 3037M  Abingdon Health PLC  20 May 2022

 

Abingdon Health plc

("Abingdon" or the "Company")

 

Exercise of Options and Total Voting Rights

 

York, U.K. 20 May 2022: Abingdon Health plc (AIM: ABDX), a leading
international developer and manufacturer of high quality and effective rapid
tests, announces that it has applied for 12,500 new ordinary shares of 0.025
pence each ("Ordinary Shares") in the Company to be admitted to trading on AIM
on 25 May 2022 following an exercise of share options.

 

Following the issue of the 12,500 new Ordinary Shares the Company will have a
total of 121,711,614 Ordinary Shares in issue. The Company does not hold any
shares in Treasury.

 

The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.

 

The above information is provided by the Company in accordance with its
obligations under the FCA's Disclosure Guidance and Transparency Rules.

 

Enquiries:

 

 Abingdon Health plc                                                                 www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                                                Via Walbrook PR
 Melanie Ross, Chief Financial Officer
 Dr Chris Hand, Non-Executive Chairman

 Singer Capital Markets (Sole Broker and Nominated Adviser)                          Tel: +44 (0)20 7496 3000
 Peter Steel, Alex Bond, Sam Butcher (Corporate Finance)
 Tom Salvesen (Corporate Broking)

 Walbrook PR Limited                                    Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                                        (mailto:abingdon@walbrookpr.com)
 Paul McManus / Phillip Marriage  Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082
 Alice Woodings                   Mob: +44 (0)7407 804 654

About Abingdon Health plc

 

Abingdon Health is a world leading developer and manufacturer of high-quality
rapid tests across all industry sectors, including healthcare and COVID-19.
Abingdon is the partner of choice for a growing global customer base and takes
projects from initial concept through to routine and large-scale manufacturing
and has also developed and marketed its own labelled tests.

 

The Company offers product development, regulatory support, technology
transfer and manufacturing services for customers looking to develop new
assays or transfer existing laboratory-based assays to a lateral flow
format.  Abingdon Health aims to support the increase in need for rapid
results across many industries and locations and produces lateral flow tests
in areas such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access to results
allows for rapid decision making, targeted intervention and can support better
outcomes. This ability has a significant role to play in improving life across
the world. To support this aim Abingdon Health has also developed AppDx(®), a
customisable image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of
this announcement via the Regulatory Information Service, this inside
information is now considered to be in the public domain.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEDZGZKMGRGZZM

Recent news on Abingdon Health

See all news